All News
Filter News
Found 1,089 articles
-
Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors
9/15/2022
Xilio Therapeutics, Inc., a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, announced the appointment of Tomas J. Heyman to the company’s board of directors.
-
SOTIO Bolsters Leadership Team with Appointment of Martin Steegmaier as Chief Scientific Officer
9/14/2022
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group,announced the appointment of Martin Steegmaier, Ph.D., MBA, as chief scientific officer.
-
InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
9/8/2022
InnoCare Pharma (HKEX: 09969) announced today that the first patient was dosed in the phase II registrational trial (Registry number: CTR20221519) of tafasitamab in combination with lenalidomide for adult patients in China who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and are not eligible for autologous stem cell transplantation (ASCT).
-
Fiona H. Marshall has been tapped as Novartis Institutes for BioMedical Research president after Jay Bradner's exit, while Tim Demuth will succeed Malte Peters for MorphoSys.
-
InnoCare Announces the Acceptance of the Biologics License Application for Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong
8/31/2022
InnoCare Pharma (HKEX: 09969) announced today the acceptance of the biologics license application (BLA) for tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT) by the Department of Health, the Hong Kong Special Administrative Region, China.
-
MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters
8/31/2022
MorphoSys AG announced that Malte Peters, M.D., the company’s Chief Research and Development Officer and Management Board member, has decided to retire at the end of 2022.
-
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022
8/30/2022
I-Mab will host conference calls and webcasts on August 30, 2022. A Mandarin session will be held at 7:00 a.m. ET and an English session will be held at 8:15 a.m. ET.
-
ScribeEMR Announces Remote Service Capability on More than 80 EMR Platforms Including the Top Five EMRs and Specialty Platforms
8/17/2022
ScribeEMR, a leading provider of real-time remote medical scribe services, announces that it has surpassed its goal to provide remote scribe services on more than 80 EMR platforms, including the top three hospital EMRs and the top five EMRs used by outpatient practices.
-
Xencor Reports Second Quarter 2022 Financial Results
8/3/2022
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, reported financial results for the second quarter ended June 30, 2022 and provided a review of recent business and clinical highlights.
-
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
8/3/2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the second quarter and first half year of 2022.
-
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
8/2/2022
Incyte (Nasdaq:INCY) today reports 2022 second quarter financial results, and provides a status update on the Company’s clinical development portfolio.
-
MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
7/28/2022
MorphoSys AG ; will publish its results for the second quarter and first half year 2022 results on August 3, 2022 at 10:00 pm CEST.
-
Pfizer Reports Second-Quarter 2022 Results
7/28/2022
Pfizer Inc. reported strong financial results for second-quarter 2022 and updated certain components of 2022 financial guidance.
-
MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
7/26/2022
MorphoSys AG announces an update of its financial guidance for 2022, after preliminary completion of the latest evaluation of MorphoSys' half year 2022 financial performance.
-
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
7/26/2022
MorphoSys AG reported preliminary U.S. net product sales of Monjuvi® for the second quarter 2022 and announced an update of its financial guidance for 2022 based on the preliminary unaudited consolidated results for the first six months 2022 and following the license agreements with Human Immunology Biosciences, Inc. for felzartamab and MOR210.
-
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City’s Early Access Program
7/22/2022
InnoCare (HKEX: 09969) today announced that tafasitamab (Minjuvi®) in combination with lenalidomide has been approved by the Health Commission and Medical Products Administration of Hainan Province, under the early access program in Boao Lecheng International Medical Tourism Pilot Zone, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).
-
The new chief executive officer of Versanis is going to push the obesity drug bimagrumab in the limelight against Novo and Lilly's drug. Here's all that you need to know.
-
Alvotech Expands its Board of Directors as part of Transition from Private to Publicly Traded Company
7/14/2022
Alvotech, a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced the expansion of its board of directors as part of its transition from a private to a publicly traded company.
-
Chronic Lymphocytic Leukemia Therapeutics Market Size, Share, Competitive Analysis, Growth Status, Top Player Analysis By 2029
7/6/2022
To understand the analysis and the chronic lymphocytic leukemia therapeutics market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
-
ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director
7/5/2022
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022.